Generated by AI
Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. Alector Inc. applies its immuno-neurology platform to target the immune dysfunction and protein-related pathology associated with conditions such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia. The company’s current portfolio includes monoclonal antibody and other biologic programs designed to restore healthy immune function in the brain, supported by biomarker-guided clinical development. It also advances Alector Brain Carrier, a proprietary blood-brain barrier platform intended to improve therapeutic delivery to the central nervous system. Headquartered in South San Francisco, California, Alector Inc. operates as a research-driven biopharmaceutical company with a focus on translating genetics, immunology, and neuroscience into treatments for severe brain disorders.
Website131 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about ALEC.
Summary of Oct 16's posts. Generated by AI.
Summary of Oct 6's posts. Generated by AI.
If you only glanced at Alector’s headline figures, the story might look confusing. Total revenue was US$7.874 million in Q2 2025 and US$3.32 million in Q2 2026, while the firm’s net loss narrowed from US$30.524 million to US$22.99 million. For Alector shareholders, the return over the past year was 49.3%, including dividends. If you had been weighing a position back in November 2025, what exactly were you being paid to believe about this business? The easy part of this move is behind Alector...
Summary of Mar 4's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Investors talking about ALEC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.